Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer response to lice study

This article was originally published in The Tan Sheet

Executive Summary

Conclusions on efficacy of Rid pediculicide cannot be drawn from recent in vitro study because University of Miami researchers "completely ignored" directions for use, Bayer says. Study in February Archives of Dermatology reported on kill rates of head lice exposed to cotton disks impregnated with OTC, Rx pediculicides (1"The Tan Sheet" March 4, 2002, p. 10). "Contrary to the method used in the study, Rid must be applied twice in a 10-day period, followed by combing on each occasion," Bayer says. "During each application lice are completely covered with Rid. The technique of placing lice on filter paper soaked with Rid, used in this study, would not be effective"...

You may also be interested in...



Pediculicide Formulation, Vehicle Differences Cited In Efficacy Study

The "large difference of efficacy" between two OTC pyrethrin products in a recent study is due to formulation and vehicle disparities in the lice remedies, researchers say in the February Archives of Dermatology

Prenatal Vitamin D Benefit In Preventing Childhood Asthma Fades By Age 6

University of Rochester researchers say a benefit of daily prenatal vitamin D in preventing asthma in children up to 3 found in their 2016 study doesn't extend until age 6. They encourage more research, including analyzing whether supplementation should continue in young children.

UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System

At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.

Topics

UsernamePublicRestriction

Register

PS093715

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel